The current biomarkers include clinicopathological factors/parameters, such as tumor size, histological grade, Ki67 expression, and expression of ER, PR and HER2-based immunohistochemistry (IHC) assays for BC subtyping [7]. The gene discussed is ERBB2; the disease is breast cancer.